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Abstract
Background: Platelet-derived growth factor (PDGF)-BB and PDGF receptor (PDGFR)-β are
mainly expressed in the developing vasculature, where PDGF-BB is produced by endothelial cells
and PDGFR-β is expressed by mural cells, including pericytes. PDGF-BB is produced by most types
of solid tumors, and PDGF receptor signaling participates in various processes, including autocrine
stimulation of tumor cell growth, recruitment of tumor stroma fibroblasts, and stimulation of
tumor angiogenesis. Furthermore, PDGF-BB-producing tumors are characterized by increased
pericyte abundance and accelerated tumor growth. Thus, there is a growing interest in the
development of tumor treatment strategies by blocking PDGF/PDGFR function. We have recently
generated a mouse model carrying an activated PDGFR-β by replacing the highly conserved aspartic
acid residue (D) 849 in the activating loop with asparagine (N). This allowed us to investigate, in an
orthotopic tumor model, the role of increased stromal PDGFR-β signaling in tumor-stroma
interactions.
Methods:  B16 melanoma cells lacking PDGFR-β expression and either mock-transfected or
engineered to express PDGF-BB, were injected alone or in combination with matrigel into mice
carrying the activated PDGFR-β (D849N) and into wild type mice. The tumor growth rate was
followed and the vessel status of tumors, i.e. total vessel area/tumor, average vessel surface and
pericyte density of vessels, was analyzed after resection.
Results: Tumors grown in mice carrying an activated PDGFR-β were established earlier than
those in wild-type mice. In this early phase, the total vessel area and the average vessel surface were
higher in tumors grown in mice carrying the activated PDGFR-β (D849N) compared to wild-type
mice, whereas we did not find a significant difference in the number of tumor vessels and the
pericyte abundance around tumor vessels between wild type and mutant mice. At later phases of
tumor progression, no significant difference in tumor growth rate was observed between wild type
mice and mutant mice, although the pericyte coverage was higher around tumor vessels from
mutant mice.
Conclusion:  Our findings suggest that the activated PDGFR-β (D849N) in the host animal
increased the total vessel area and the average vessel surface even in PDGF-negative tumors,
resulting in a shorter lag phase during tumor establishment.
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Background
Platelet-derived growth factor (PDGF)-BB is a
homodimeric growth factor with a broad range of target
cells, notably mesoderm-derived cells, such as pericytes
and mesangial cells, but also ectoderm-derived glial cells
and neurons. PDGF-BB binds to two distinct receptor
tyrosine kinases denoted PDGF receptor (PDGFR)- α and
– β [1].
PDGF-BB and PDGFR-β are mainly expressed in the devel-
oping vasculature, where PDGF-BB is produced by
endothelial cells which attract PDGFR-β expressing mural
cells, i.e. pericytes and vascular smooth muscle cells [2-4].
Knockout studies of PDGF-B or PDGFR-β identified peri-
cyte deficiency of the microvasculature as a main pheno-
type, resulting in lethal hemorrhage and edema at late
gestation [5-7].
PDGF-BB is produced by most types of solid tumors,
inducing stroma formation and neovascular response in
order to secure sufficient supply of nutrients and oxygen
[8]. Furthermore, it has been shown that PDGFR-β expres-
sion by pericytes is necessary for their recruitment to
tumor vessels and that extracellular retention of PDGF-BB
produced by the tumor endothelium is required for the
recruitment of adequate numbers of pericytes, as well as
for proper integration of pericytes into the vascular wall
[9]. A recent study demonstrated that pericyte density cor-
relates inversely with the effect of antiangiogenic therapy
[10]. Using mouse models it was shown that inhibition of
PDGF signaling reduces interstitial fluid pressure in
tumors, and thereby enhances the effect of chemotherapy
[11,12]. Together, these examples suggest potential bene-
fits of targeting PDGFR-β in the treatment of tumors.
Recently, PDGF receptor signaling was shown to be per-
turbed by mutations within the activation loop of
PDGFR-α in a subset of wild-type c-kit expressing gas-
trointestinal stromal tumors (GISTs) [13]. One of these
mutations, D842V, resulted in receptors displaying lig-
and-independent receptor phosphorylation and activa-
tion of downstream signaling molecules [14]. We have
recently generated a mouse model carrying a mutation in
the corresponding amino acid residue in the activation
loop of the murine PDGFR-β; namely an exchange of
asparagine for aspartic acid at amino acid position 849
(D849N). This mutation did not cause any tumor forma-
tion in homozygous mutant mice, despite the fact that
this mutation also caused ligand-independent receptor
autophosphorylation [15]. This elevated basal phosphor-
ylation resulted in a dramatically increased ligand-inde-
pendent anti-apoptotic signaling and migration, as well as
a ligand-dependent increase in proliferation of D849N-
mutant mouse embryonic fibroblasts. This prompted us
to investigate how a host environment carrying a D849N-
activated PDGFR-β would influence tumor formation in
vivo.
In the present study, we show that a stromal environment
with the D849N-mutant PDGFRβ favored earlier estab-
lishment of PDGF-BB expression-negative tumors up to a
size of 0.3 cm3, due to increased vascularization, charac-
terized by increased total vessel area and average vessel
surface. Above a tumor size of 0.3 cm3, the tumor growth
rate was similar in wild type and D849N-mutant mice.
Methods
Cell culture
B16F10 melanoma cells stably transfected with either
empty expression vector (mock) or vector containing an
expression cassette for PDGF-B were cultured in Dul-
becco's modified Eagle's medium (DMEM) supplemented
with 10% fetal bovine serum and antibiotics [16].
Animals
Generation of D849N-mutant mice carrying an activating
mutation in the PDGFR-β have been described earlier
[15]. Mutant and control mice were in identical C57Bl/6
strain background. All animal experiments were approved
by the local ethical committee and performed according
to the United Kingdom Coordinating Committee on Can-
cer Research guidelines [17].
Tumor formation assay
B16 melanoma cells (1 × 106 mock-transfected or PDGF-
BB expressing cells) were injected subcutaneously in 100
µl PBS on both sides of the dorsal region of mice anesthe-
tized with isoflurane. The tumor size was obtained by
daily measurements of the length and width of the tumor
nodules with calipers. The tumor volume was calculated
as 3.14/6 × length × width2. Tumors were removed surgi-
cally from CO2-sacrificed mice at maximum tumor size of
0.8–1.0 cm3 and fixed in paraformaldehyde overnight.
After embedding tumors in paraffin, sections were cut at
4-µm thickness onto Superfrost Plus slides (Histolab) for
Hematoxylin and Eosin (H & E) staining or immunostain-
ing.
Matrigel injection
Matrigel (BD Biosciences, #354248, high concentration;
150 µl) was mixed by pipetting with 1 × 106 B16 cells
resuspended in 150 µl of PBS, or 150 µl of PBS alone.
Matrigel mixes (300 µl) were injected subcutaneously on
both sides of the ventral region of wild type and mutant
(D849N) mice under isoflurane anesthesia. Matrigel
plugs were harvested at the indicated time points and
fixed in paraformaldehyde overnight. After embedding
matrigel plugs in paraffin, sections were cut at 4-µm thick-
ness onto Superfrost Plus slides.BMC Cancer 2007, 7:224 http://www.biomedcentral.com/1471-2407/7/224
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Histochemistry and immunohistochemistry
For immunohistochemistry, deparaffinized sections were
pretreated by boiling in 10 mM citrate buffer (pH 6.0) for
2 × 7 min at 750 W in a microwave oven. Tissue peroxi-
dase activity was quenched by incubation in 3% H2O2 in
PBS for 10 min, followed by blocking in 20% serum of the
secondary antibody species. For double staining of peri-
cytes and endothelial cells, anti- α smooth muscle actin
(ASMA) monoclonal antibodies (1 µg/ml; clone 1A4,
Dako) and goat-anti-mouse CD31/platelet/endothelial
cell adhesion molecule 1 (PECAM-1) antibodies (1 µg/ml
sc-1506; Santa Cruz Biotechnology) were used consecu-
tively. Macrophages were identified with rat anti-mouse
F4/80 antibodies (1:100, MCAP497, clone A3-1, Serotec).
Omission of primary antibody was used as negative con-
trol. Primary antibodies for ASMA, CD31 and F4/80 were
detected using either biotinylated rabbit-anti-mouse anti-
bodies (1:500, E0354, DAKO) visualized by Vectastain
ABC-HRP kit (1:100, Vector Laboratories), or biotinylated
rabbit-anti-goat antibodies (1:500, E0466, DAKO) visual-
ized by Vectastain ABC-AP kit (1:100, Vector Laborato-
ries), or biotinylated goat-anti-rat antibodies (10 µg/ml,
BA9400, VECTOR) visualized by Vectastain ABC-HRP kit
(1:100, Vector Laboratories) respectively, according to the
manufacturer's instructions. Mayer's hematoxylin was
used as counterstain. Using a Leica microscope (DM4000)
equipped with a Leica DFC camera and Qwin software,
several parameters, such as the total vessel surface, viable
tumor area, number of vessels and pericytes and perimeter
of vessels, were calculated. All immunohistochemical
analyses were performed on 20 high-power fields per
tumor. Only viable tumor area was examined. The ratio of
total vessel area per tumor was defined as the total surface
of vessel area divided by the area of viable tumor. The
average vessel area was defined as total vessel area divided
by the total number of vessels. The number of vessels per
high-power field was defined as total number of vessels
divided by the number of analyzed fields (n = 20). The
numerical density of pericytes per perimeter of vessel was
defined as the number of pericyte nuclei associated with
tumor vessels divided by the sum of vessel perimeter.
Statistical analysis
Statistical analysis was performed using ANOVA. P < 0.05
was considered as statistically significant.
Results
PDGF-BB expression increases tumor vascularization in 
wild type and D849N-mutant mice but has no further 
increasing effect on pericyte coverage in D849N-mutant 
mice
It has been shown that the ectopic expression of PDGF-BB
by subcutaneously injected melanoma cells has a positive
effect on tumor vascularization [16]. Therefore, we first
analyzed the effect of PDGF-BB-expression on the vascular
compartment in large (0.8 cm3) B16 tumors in wild type
mice and D849N-mutant mice (n = 6 tumors for each
experimental group). Staining for CD31 identified
endothelial cells, whereas perivascular cells/pericytes were
identified by staining for ASMA. In both wild type and
D849N-mutant mice, the ratio of vessel area/tumor area
was higher for PDGF-BB-expressing B16-tumors, com-
pared to mock-transfected B16-tumors (wild type p <
0.05, D849N-mutant p < 0.01) (Fig. 1A). However for
PDGF-BB expressing tumors, there was only a tendency (p
= 0.1371) towards an increased ratio of vessel area/tumor
area in D849N-mutant mice (0.065 +/- 0.022) compared
to wild type mice (0.049 +/-0.014) (Fig. 1A). The average
vessel surface, defined as the total vessel area divided by
the number of vessels, was increased in PDGF-BB-express-
ing compared to wild type B16 tumors, grown in wild type
(p < 0.0001), as well as D849N-mutant mice (p < 0.01)
(Fig. 1B). Furthermore, the average vessel surface of
PDGF-BB-expressing tumors was slightly higher in
D849N-mutant mice (2362 +/- 824) than in wild-type
mice (1679 +/- 301), although the difference was not sta-
tistically significant (p = 0.0649) (Fig. 1B). On the other
hand, the number of vessels per high-power field in
PDGF-BB-expressing tumors was decreased in wild type
mice (p < 0.001) and D849N-mutant mice (p < 0.01)
compared to wild type tumors (Fig. 1C).
Since pericyte recruitment is a well-documented effect of
PDGF signaling, we calculated the pericyte density of ves-
sels as the total number of pericytes divided by the total
perimeter of vessels. PDGF-BB-expression significantly
increased the pericyte density in B16 tumors (0.8–1.0
cm3) grown in wild type mice (p < 0.001) (Fig. 1D). Such
an effect was not observed for tumors grown in D849N-
mutant mice. Instead, in comparison to the wild type B16
tumors grown in wild type mice, those grown in D849N-
mutant mice generally displayed increased pericyte num-
bers per vessel perimeter, independent of tumoral PDGF-
BB expression (p < 0.05) (Fig. 1D). We confirmed these
initial findings in another experimental series, in which
we only used mock-transfected B16 melanoma cells
(twelve tumors each from wild type and D849N-mutant
mice). Again, increased pericyte density of B16 tumor vas-
culature was the only statistically significant difference
between tumors grown in wild type and in D849N-
mutant mice (Fig. 2F).
Activated PDGFR-β accelerates B16 tumor growth
In order to test if the increased pericyte coverage has any
functional consequences on tumor development, we
measured the tumor growth rate, i.e. the number of days
needed from the injection time point until tumors had
reached sizes of 0.2, 0.3, 0.5, or 0.8 cm3 in eight wild type
and eight D849N-mutant mice. Tumors in D849N-
mutant mice grew significantly faster predominantly dur-BMC Cancer 2007, 7:224 http://www.biomedcentral.com/1471-2407/7/224
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ing the early establishment of the tumor, i.e. until it had
reached a volume of 0.3 cm3. This took 20.1 days (19.4 for
0.2 cm3) in mutant mice, compared to 23.4 days (22.5 for
0.2 cm3) in wild type mice (p = 0.047<0.05 for 0.3 cm3; p
= 0.0216 for 0.2 cm3; Fig. 3A and data not shown). We
also observed slightly increased growth rates at later
stages, although this was not statistically significant (0–
0.5 cm3, p = 0.097; 0–0.8 cm3, p = 0.065; Fig. 3B and Fig.
3C).
The mutant PDGFR-β causes increased tumor 
vascularization, supporting early tumor establishment
Based on the above results one might speculate that the
increased pericyte coverage of the tumor vasculature
PDGF-BB expression increases vascularization of B16 tumors Figure 1
PDGF-BB expression increases vascularization of 
B16 tumors. (A)-(D): Mock-transfected B16 melanoma 
cells, lacking PDGF-BB expression (Mock) and PDGF-BB 
expressing B16 melanoma cells (BB) were subcutaneously 
injected on both sides of the midline of the lower dorsal 
abdomen of wild type (wt) or D849N-mutant mice (mut). Six 
tumors were analyzed for each experimental combination. 
When the B16 melanomas had reached 0.8 cm3, they were 
removed and analyzed for ratio of total vessel area/viable 
tumor (A), average vessel surface (B), number of vessels per 
high-power field (C) and numerical density of pericytes per 
perimeter of vessel (D). Asterisks indicate statistical signifi-
cance (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 
0.0001) by Student's t-test.
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D849N-mutant PDGFR-beta results in increased pericyte  coverage of vessels Figure 2
D849N-mutant PDGFR-beta results in increased per-
icyte coverage of vessels. B16 melanoma mock cells, 
which do not produce PDGF-BB, were subcutaneously 
injected and processed as described in the legend of figure 1. 
Double immunohistochemical staining for endothelial cells 
(CD31, blue) and perivascular cells (α-smooth muscle actin, 
brown) in B16 melanoma is shown. Please note the small ves-
sels (blue) covered by few pericyte (brown) in tumors grown 
in wild type mice (A) compared to larger vessels surrounded 
by multiple perivascular cells (brown) in tumors grown in 
D849N-mutant mice (B). Tissue sections were analyzed for 
total vessel area (C), average vessel surface (D), number of 
vessels per high-power field (E) and numerical density of per-
icytes per vessel perimeter (F). Asterisk indicates statistical 
significance (*, p < 0.01) by Student's t-test.
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observed in D849N-mutant mice could cause accelerated
establishment of tumors due to improved vessel function.
However, it is technically very difficult to follow the early
stages of tumor establishment from subcutaneously
injected cells. We therefore mixed tumor cells with
matrigel before injection in order to make it easier to
localize the early stages of tumor establishment [18].
Matrigel plugs were removed 8 (a) or 10 (b) days after
injection, and the tumor vessel status was analyzed as
described before (a: n = 5 plugs each from wild type and
D849N-mutant mice; b: n = 9 plugs from wild type mice,
n = 13 plugs from D849N-mutant mice). At both time
points, the ratio of vessel area per tumor was significantly
higher in mutant (a = 2.35%, b = 3.35%) than wild type
mice (a = 1.03%, b = 1.59%) (Fig. 4A and data not
shown). Furthermore, the average vessel area was (a)
2.62- and (b) 3.24-times larger in mutant mice than in
wild type mice (a, p < 0.01; b, p < 0.01; Fig. 4B and data
not shown). Surprisingly, no difference in the number of
vessels and pericyte density could be observed at this early
time point of tumor development (Fig. 4C and 4D, and
data not shown). These observations indicated that the
early establishment of tumors in mice with D849N-
mutant PDGFR was not caused by increased pericyte cov-
erage, but by increased vascularization (ratio of vessel area
per tumor and average vessel area) and thus improved
blood supply.
D849N-mutant ASMA-positive cells are characterized by 
accelerated matrigel invasion
PDGFR-β-expressing cells, such as macrophages, fibrob-
lasts and perivascular cells, have been shown to pave the
way for new vessels [1,19]. Since we observed a strongly
D849N-mutant PDGFR-beta increases the ratio of vessel  area per tumor and average vessel area Figure 4
D849N-mutant PDGFR-beta increases the ratio of 
vessel area per tumor and average vessel area. 
Matrigel mixed with mock-transfected B16 melanoma cells 
was subcutaneously injected into mice and processed after 8 
days as described in the legend of figure 2. Tissue sections 
were analyzed for the ratio of total vessel area/tumor (A), 
average vessel surface (B), number of vessels per high-power 
field (C) and numerical density of pericytes per perimeter of 
vessel (D). Asterisks indicate statistical significance (*, p < 
0.01) by Student's t-test. Double immunohistochemical stain-
ing for vessels (CD31, blue) and perivascular cells (alpha-
smooth muscle actin, brown) identify significantly larger ves-
sels in B16 melanoma/matrigel plugs grown in wild type mice 
(E) compared to D849N-mutant mice (F) (the same magnifi-
cation was used in Fig. 4E and Fig. 4F).
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Accelerated tumor establishment in D849N-mutant mice Figure 3
Accelerated tumor establishment in D849N-mutant 
mice. The average time required until injected tumor cells 
reached volumes of 0.3 (A), 0.5 cm3 (B) and 0.8 cm3 (C), 
respectively, are shown. Asterisk indicates statistical signifi-
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increased ligand-independent migration in D849N-
mutant mouse embryonic fibroblasts [15], we tested if
stromal cells of the mutant mouse would invade matrigel
plugs more efficiently than those from wild type mouse.
matrigel plugs harvested 6 days after injection from wild
type (n = 10) or mutant mice (n = 9) were equally positive
for the monocyte/macrophage marker F4/80 (data not
shown). However, we found more ASMA-positive cells in
the matrigel plugs of mutant mice, indicating a more inva-
sive/motile stromal compartment in mice carrying the
activated PDGFR-β (Fig. 5).
Discussion
The crucial importance of PDGF-B and PDGFR-β for ves-
sel formation and maturation has been unambiguously
demonstrated by gene targeting experiments [4]. In our
study, ectopic PDGF-BB expression by B16 melanoma
cells correlated with increased vascularization and peri-
cyte coverage in established, large (0.8–1.0 cm3) tumors.
This is in accordance with previous studies indicating that
PDGF-BB induces more mature vessels with higher peri-
cyte density [9,10,16]. Interestingly, we found the pericyte
density elevated in mice carrying an activating mutation
(D849N) in PDGFR-β, independent of ectopic PDGF-BB
expression, supporting earlier observations that this
mutation causes significant receptor signaling in the
absence of ligand, or greatly increases sensitivity towards
very low amounts of ligand [15]. Since the pericyte cover-
age of the tumor vasculature in D849N-mutant mice was
autonomously elevated, we continued our experiments
with B16 melanoma cells lacking PDGF-BB expression. In
several mouse tumor models, it has been shown that para-
crine stimulation of PDGFR-β is associated with increased
tumor growth rate [16,20]. In agreement with this, we
found that tumors grew faster in mice with activated
PDGFR-β, compared to wild type mice. However, this was
statistically significant only during tumor establishment,
i.e. until a volume 0.2 to 0.3 cm3. In order to investigate
the influence of the host stroma on early tumor establish-
ment, we mixed B-16 melanoma cells with matrigel. In
contrast to the situation in large tumors (0.8–1.0 cm3),
there was no difference in pericyte density, but the tumors
grown in D849N-mutant mice were characterized by sig-
nificantly increased vascularization. Therefore, the growth
advantage during tumor establishment is most probably
due to increased blood supply. Experimental angiogenesis
is characterized by a sequential invasion of subcutaneous
matrigel plugs by monocyte/macrophages, fibroblasts,
pericytes and endothelial (precursor) cells [19]. Although
we did not see any difference in macrophage staining in
subcutaneous matrigel plugs lacking tumor cells (data not
shown), we found that ASMA-positive stromal cells in
D849N-mutant mice more efficiently invaded matrigel
plugs. This implies that a more active stromal compart-
ment probably drives the improved vascularization dur-
ing tumor establishment in mice carrying an activated
PDGFR-β. On the other hand, it seems unlikely that an
enhanced direct interaction between stromal fibroblasts
and tumor cells could account for the earlier tumor estab-
lishment in D849N-mutant mice, since there was no dif-
ference in proliferation of B16 melanoma cells co-
cultured with either irradiated wild type or irradiated
D849N-mutant mouse embryonic fibroblasts in vitro
(data not shown). However, we cannot exclude an
increased participation of circulating hemangioblasts
(hematopoietic/endothelial precursor cells) in early
tumor vascularization in D849N-mutant mice. Recently,
increased PDGFR-β signaling due to transgenic overex-
pression of PDGF-B, or the D849N-mutant PDGFR-β was
shown to promote endothelial cell differentiation of
hemangioblasts in vivo at the expense of hematopoietic
differentiation [21].
Conclusion
In summary, we have found two different effects of
D849N-mutant PDGFR-β signaling in our melanoma
mouse model. During late phase, when the tumor is char-
acterized by remodeling of necrotic areas and tumor re-
growth, tumor vessels provided by the D849N-mutant
host stroma are more densely covered by perivascular
cells, but this does not to result in any appreciable tumor
growth advantage. During early phases of tumor develop-
ment however, the mutant host stroma supports the
Immunohistochemical staining for α-smooth muscle actin Figure 5
Immunohistochemical staining for α-smooth muscle 
actin. Immunohistochemical staining for α-smooth muscle 
actin (ASMA, brown) showing clearly more ASMA-positive 
cells in the matrigel plugs of mice carrying the activated 
PDGFR-beta (B), compared wild type mice (A) (the same 
magnification was used in Fig.5A and Fig.5B).
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establishment of tumor more efficiently, due to increased
vascularization. This is an important observation, as it
demonstrates that activating mutations of growth factor
receptors in the host stroma can accelerate tumor estab-
lishment in the absence of tumor-derived ligand expres-
sion, and thus contribute to shortened tumor dormancy.
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